Triptans is named as an intervention in 2 current clinical trials in our China, Japan and Egypt registers. 1 is recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Guangdong Provincial People's Hospital (1). The most-studied condition is Migraine.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Assessment of Oral Caffeine Intake in Changing the Severity of Acute Migraine Attack Using VAS Score Among Patients Attending Headache and Neurology Outpatients Clinic of Ainshams University Hospitals
NCT07022496 · ClinicalTrials.gov ↗ · Migraine, Migraine Disease, Migraine Headache
|
Phase 4 | Recruiting | Ain Shams University | Egypt |
|
Effectivity and Safety of PFO Closure vs Medicine in Alleviating Migraine
NCT04946734 · ClinicalTrials.gov ↗ · PFO - Patent Foramen Ovale, Migraine
|
Phase 3 | Active, closed | Guangdong Provincial People's Hospital | China, Japan |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Guangdong Provincial People's Hospital | 1 |
| Ain Shams University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 1 | 0 |
| Clinical trials in Japan | 1 | 0 |
| Clinical trials in Egypt | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China, Japan and Egypt registers name Triptans as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in Egypt. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Guangdong Provincial People's Hospital (1) and Ain Shams University (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Triptans works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Triptans works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Triptans (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.